The Cannabis ETF (THCX)
ARCA ARCA Primary Summary
THCX Chart
3 Marijuana Stocks For Cannabis Real Estate Investors
Is it safe to invest in marijuana stocks with the entire sector trading at all-time lows? If the legal market is profitable and companies are performing well, why are the top marijuana stocks not trading? These are just some of the questions that plague investors and shareholders. The answer is not so simple, which can make things a bit more complex to understand. Although legal cannabis as a business is thriving and growing in all areas, this has not translated to the public sector so well.
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.
Cultivate Your Portfolio: U.S. Cannabis Stocks for May 2025
In recent weeks, cannabis penny stocks have attracted cautious investor interest. First, the U.S. legal cannabis market reached $33.6 billion in 2023. Moreover, it is projected to grow at a 12.1 percent CAGR through 2030. Meanwhile, employment in the sector surpassed 440,000 full‑time jobs nationwide. At the same time, federal reform remains stalled despite rescheduling momentum. For instance, the DEA's proposed move to Schedule III could reshape banking access. In addition, states push new bills. Notably, Pennsylvania lawmakers debate privatized dispensaries to unlock $250 million in annual tax revenue. Likewise, the Supreme Court's recent RICO decision heightens compliance risks across the industry. Therefore, cannabis penny stocks offer both opportunity and volatility this week. Consequently, traders should combine fundamental awareness with market context before entry.
The Cannabis ETF (THCX) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
The Cannabis ETF Profile
| - Industry | - Sector | - CEO | ARCA Exchange | 84858T400 CUSIP |
| United States Country | - Employees | - Last Dividend | 9 Aug 2023 Last Split | - IPO Date |
Overview
The fund is tailored to investors aiming to capitalize on the burgeoning cannabis industry by focusing its investment strategy predominantly on the entities within this rapidly growing sector. It pledges to allocate at least 80% of its total assets to the securities that comprise its primary index, ensuring a significant exposure to the cannabis industry. Furthermore, under normal circumstances, it commits to investing a similar portion of its net assets, plus any borrowings for investment purposes, into exchange-listed common stocks or corresponding American Depositary Receipts (ADRs) of Cannabis Companies. The guiding index for the fund is a proprietary, rules-based construct specially designed to mirror the performance of a curated portfolio of Cannabis Companies. Noteworthily, the fund operates with a non-diversified status, indicating a potentially higher risk and reward ratio due to its concentrated investment focus.
Products and Services
- Investment in Component Securities
- Investment in Exchange Listed Cannabis Stocks and ADRs
- Tracking the Proprietary Rules-Based Index
The fund dedicates at least 80% of its total assets to investing in the securities that are integral to its main index. This approach ensures significant exposure to the cannabis sector, promising investors direct access to the performance of pivotal companies within this domain.
Emphasizing its focus on the cannabis industry, the fund invests at least 80% of its net assets, in addition to borrowings for investment purposes, in either exchange-listed common stock or corresponding ADRs of select Cannabis Companies. This strategy caters to investors seeking to gain from the equity market movements of leading and emerging companies in the cannabis sector.
The fund’s investment strategy is closely aligned with a proprietary, rules-based index that is meticulously crafted to follow the performance of a portfolio comprising Cannabis Companies. This index serves as a critical benchmark, guiding the fund's investment allocations and decisions with the aim to replicate or exceed its performance.
